PE20171058A1 - Composiciones y metodos de uso para tratar trastornos metabolicos - Google Patents
Composiciones y metodos de uso para tratar trastornos metabolicosInfo
- Publication number
- PE20171058A1 PE20171058A1 PE2017000582A PE2017000582A PE20171058A1 PE 20171058 A1 PE20171058 A1 PE 20171058A1 PE 2017000582 A PE2017000582 A PE 2017000582A PE 2017000582 A PE2017000582 A PE 2017000582A PE 20171058 A1 PE20171058 A1 PE 20171058A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- sequence
- compositions
- methods
- metabolic disorders
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073737P | 2014-10-31 | 2014-10-31 | |
| US201562244604P | 2015-10-21 | 2015-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171058A1 true PE20171058A1 (es) | 2017-07-21 |
Family
ID=55851475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000582A PE20171058A1 (es) | 2014-10-31 | 2015-10-29 | Composiciones y metodos de uso para tratar trastornos metabolicos |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9920118B2 (enExample) |
| EP (2) | EP3212226B1 (enExample) |
| JP (1) | JP6722175B2 (enExample) |
| KR (1) | KR102672706B1 (enExample) |
| CN (2) | CN115043945A (enExample) |
| AP (1) | AP2017009828A0 (enExample) |
| AU (1) | AU2015339130C1 (enExample) |
| CL (1) | CL2017000864A1 (enExample) |
| CO (1) | CO2017003487A2 (enExample) |
| DK (1) | DK3212226T3 (enExample) |
| DO (1) | DOP2017000097A (enExample) |
| EA (1) | EA036985B1 (enExample) |
| EC (1) | ECSP17021754A (enExample) |
| ES (1) | ES2799503T3 (enExample) |
| GT (1) | GT201700072A (enExample) |
| IL (1) | IL251066B (enExample) |
| MD (1) | MD20170035A2 (enExample) |
| MX (1) | MX357994B (enExample) |
| MY (1) | MY186702A (enExample) |
| NI (1) | NI201700042A (enExample) |
| PE (1) | PE20171058A1 (enExample) |
| PH (1) | PH12017500680A1 (enExample) |
| PL (1) | PL3212226T3 (enExample) |
| PT (1) | PT3212226T (enExample) |
| SG (1) | SG11201702580PA (enExample) |
| SV (1) | SV2017005420A (enExample) |
| TN (1) | TN2017000113A1 (enExample) |
| TW (1) | TWI703161B (enExample) |
| UA (1) | UA121973C2 (enExample) |
| WO (1) | WO2016069921A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| BR112015018104A2 (pt) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| UA121973C2 (uk) | 2014-10-31 | 2020-08-25 | Нджм Біофармасьютікалз, Інк. | Комплекс, що має активність фактора диференціації росту 15 (gdf15), та способи лікування ним ожиріння та гіперглікемії у суб'єкта |
| JP6830437B2 (ja) | 2014-12-10 | 2021-02-17 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織および臓器 |
| JP7014724B2 (ja) | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリンおよびその使用 |
| IL261666B2 (en) | 2016-03-31 | 2024-09-01 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| CN109414471A (zh) | 2016-05-24 | 2019-03-01 | 诺和诺德股份有限公司 | Mic-1化合物及其用途 |
| CN117143247A (zh) * | 2016-07-19 | 2023-12-01 | 伊班绰斯有限责任公司 | 双特异性蛋白质及其制备方法 |
| WO2018035084A1 (en) * | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| EP3538124A4 (en) * | 2016-11-13 | 2020-07-22 | Imagine Pharma | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA |
| JP7134960B2 (ja) * | 2016-12-06 | 2022-09-12 | セントビンセンツ ホスピタル シドニー リミテッド | 肥満及び摂食障害の治療 |
| EP3681529A1 (en) | 2017-09-10 | 2020-07-22 | Novo Nordisk A/S | Mic-1 and glp-1 for use in the treatment of obesity |
| CA3090322A1 (en) | 2018-02-12 | 2019-08-15 | Diabetes-Free, Inc. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| JOP20200258A1 (ar) * | 2018-04-09 | 2020-10-11 | Amgen Inc | البروتينات الاندماجية لعامل تمايز النمو 15 |
| AU2019263850A1 (en) | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| CN112543869A (zh) | 2018-08-10 | 2021-03-23 | 诺华股份有限公司 | Gfral细胞外结构域和使用方法 |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| ES3011982T3 (en) | 2018-10-22 | 2025-04-08 | Janssen Sciences Ireland Unlimited Co | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| EP3934679A1 (en) * | 2019-03-08 | 2022-01-12 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
| EP3978518A4 (en) * | 2019-04-23 | 2022-11-02 | Lg Chem, Ltd. | Fusion polypeptide comprising fc region of immunoglobulin and gdf15 |
| EP3999544A4 (en) * | 2019-07-19 | 2023-08-09 | Wuxi Xdc Singapore Private Limited | POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| WO2021107603A2 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| CA3159979A1 (en) * | 2019-12-11 | 2021-06-17 | Yeonchul Kim | Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation |
| CN111499764B (zh) * | 2020-04-02 | 2022-02-08 | 北京翼方生物科技有限责任公司 | 一种具有促红细胞生成素活性的长效融合蛋白 |
| CN111887828B (zh) * | 2020-07-08 | 2021-05-07 | 中南大学湘雅医院 | 围术期患者非接触式生理信息监测装置、计算机设备和存储介质 |
| DE102020122214B4 (de) | 2020-08-25 | 2026-01-29 | Kulzer Gmbh | Verfahren und Vorrichtung zum Kürzen von Prothesenzähnen für Dentalprothesen |
| US20250382359A1 (en) | 2021-12-22 | 2025-12-18 | Byomass Inc. | Targeting gdf15-gfral pathway |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| WO2025217523A1 (en) * | 2024-04-12 | 2025-10-16 | 23Andme, Inc. | Variant hinge and molecules comprising same |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
| US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
| US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
| US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
| US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
| US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
| US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
| US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
| US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
| US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
| US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
| US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE423788T1 (de) | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | Neues tgf-beta-ahnliches cytokin |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| JP2001500732A (ja) | 1996-09-11 | 2001-01-23 | オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド | 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法 |
| ATE253073T1 (de) | 1997-03-07 | 2003-11-15 | Metabasis Therapeutics Inc | Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| EP1100822A1 (en) | 1998-07-23 | 2001-05-23 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
| EP1112275B9 (en) | 1998-09-09 | 2004-03-10 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1179067B1 (en) | 1999-05-17 | 2006-12-13 | BIOPHARM Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH | Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| NZ521732A (en) | 2000-03-22 | 2004-05-28 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines and factor VIII muteins |
| EP1276856A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| AU2001250182B2 (en) | 2000-04-20 | 2006-06-08 | St Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| JP2005500815A (ja) | 2000-12-29 | 2005-01-13 | キュラジェン コーポレイション | タンパク質およびそれをコードする核酸 |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| HU229910B1 (hu) | 2001-05-11 | 2014-12-29 | Amgen Inc Thousand Oaks | A TALL-1-hez kötõdõ peptidek és rokon molekulák |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| CA2504508A1 (en) | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| CA2561877C (en) | 2004-04-13 | 2017-03-14 | St. Vincent's Hospital Sydney Limited | Use of mic-1 or modulating agent thereof to modulate appetite or body weight |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| RU2401842C2 (ru) | 2004-10-08 | 2010-10-20 | Домантис Лимитед | Антагонисты и способы их применения |
| PL1844337T3 (pl) | 2005-01-24 | 2013-12-31 | Pepscan Systems Bv | Związki wiążące, związki immunogenne i peptydomimetyki |
| JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
| US7566565B2 (en) | 2006-03-24 | 2009-07-28 | Syntonix Pharmaceuticals, Inc. | PC5 as a factor IX propeptide processing enzyme |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| JP2009539767A (ja) | 2006-06-02 | 2009-11-19 | ワイス | 精製および治療方法のためのＴＧＦ−βスーパーファミリータンパク質およびペプチドの使用 |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| EP2052253A2 (en) | 2006-07-26 | 2009-04-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
| CA2660691C (en) | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| CA2685148C (en) | 2007-04-25 | 2014-09-09 | Stem Cells Spin Sp.Z.O.O. | New stem cell lines, their application and culture methods |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| AU2008310310A1 (en) | 2007-10-09 | 2009-04-16 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| US20110039284A1 (en) | 2007-10-22 | 2011-02-17 | Samuel Norbert Breit | Methods of prognosis |
| KR20100087344A (ko) | 2007-10-29 | 2010-08-04 | 버지니아 테크 인터렉추얼 프라퍼티스, 인크. | 돼지 ＤＣ-ＳＩＧＮ, ＩＣＡＭ－３ 및 ＬＳＥＣｔｉｎ 및 이의 용도 |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| JP2011509403A (ja) | 2008-01-08 | 2011-03-24 | エフ．ホフマン−ラ ロシュ アーゲー | Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法 |
| JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| WO2009121804A1 (en) | 2008-03-31 | 2009-10-08 | Glaxo Group Limited | Drug fusions and conjugates |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| EP2350669B9 (en) | 2008-10-31 | 2014-06-11 | St Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
| KR101798474B1 (ko) | 2008-10-31 | 2017-11-16 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화 |
| KR20100054711A (ko) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| AU2010213575B2 (en) | 2009-02-12 | 2013-11-14 | Stryker Corporation | Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| WO2010099219A2 (en) | 2009-02-24 | 2010-09-02 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
| AU2010246108B2 (en) | 2009-05-05 | 2014-10-23 | Amgen Inc. | FGF21 mutants and uses thereof |
| US9308258B2 (en) | 2009-07-08 | 2016-04-12 | Amgen Inc. | Stable and aggregation free antibody FC molecules through CH3 domain interface engineering |
| US20130323835A1 (en) | 2009-07-15 | 2013-12-05 | Zirus, Inc. | Mammalian Genes Involved in Infection |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| ES2636971T3 (es) | 2009-11-05 | 2017-10-10 | F. Hoffmann-La Roche Ag | Procedimientos y composición para la secreción de polipéptidos heterógenos |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
| US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| EP2609427B1 (en) | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| US10752664B2 (en) | 2011-04-08 | 2020-08-25 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| EP3144320B9 (en) | 2011-04-13 | 2018-08-22 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| CN107090038A (zh) | 2011-06-30 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 抗c‑met抗体配制剂 |
| MX340498B (es) | 2011-06-30 | 2016-07-11 | Chugai Pharmaceutical Co Ltd | Polipeptido heterodimerizado. |
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| EP2882774B1 (en) | 2012-08-08 | 2018-10-03 | Roche Glycart AG | Interleukin-10 fusion proteins and uses thereof |
| EP2934584B1 (en) | 2012-12-21 | 2020-02-19 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| BR112015018104A2 (pt) * | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| RS57393B1 (sr) | 2013-03-15 | 2018-09-28 | Hoffmann La Roche | Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu |
| CN203123206U (zh) | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
| SG11201600734YA (en) * | 2013-07-31 | 2016-02-26 | Amgen Inc | Stabilization of fc-containing polypeptides |
| UY35686A (es) | 2013-07-31 | 2015-01-30 | Amgen Inc | Construcciones del factor de diferenciación de crecimiento 15 (gdf-15) |
| WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| UA121973C2 (uk) | 2014-10-31 | 2020-08-25 | Нджм Біофармасьютікалз, Інк. | Комплекс, що має активність фактора диференціації росту 15 (gdf15), та способи лікування ним ожиріння та гіперглікемії у суб'єкта |
| CN108367053A (zh) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
| EP3978518A4 (en) | 2019-04-23 | 2022-11-02 | Lg Chem, Ltd. | Fusion polypeptide comprising fc region of immunoglobulin and gdf15 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
-
2015
- 2015-10-29 UA UAA201702260A patent/UA121973C2/uk unknown
- 2015-10-29 MX MX2017005237A patent/MX357994B/es active IP Right Grant
- 2015-10-29 MD MDA20170035A patent/MD20170035A2/ro not_active Application Discontinuation
- 2015-10-29 PL PL15855147T patent/PL3212226T3/pl unknown
- 2015-10-29 US US14/927,153 patent/US9920118B2/en active Active
- 2015-10-29 AU AU2015339130A patent/AU2015339130C1/en active Active
- 2015-10-29 PE PE2017000582A patent/PE20171058A1/es unknown
- 2015-10-29 TN TN2017000113A patent/TN2017000113A1/en unknown
- 2015-10-29 TW TW104135611A patent/TWI703161B/zh active
- 2015-10-29 JP JP2017514327A patent/JP6722175B2/ja active Active
- 2015-10-29 DK DK15855147.3T patent/DK3212226T3/da active
- 2015-10-29 EA EA201790405A patent/EA036985B1/ru unknown
- 2015-10-29 CN CN202210429627.3A patent/CN115043945A/zh active Pending
- 2015-10-29 CN CN201580049362.2A patent/CN106687128B/zh active Active
- 2015-10-29 WO PCT/US2015/058111 patent/WO2016069921A1/en not_active Ceased
- 2015-10-29 AP AP2017009828A patent/AP2017009828A0/en unknown
- 2015-10-29 PT PT158551473T patent/PT3212226T/pt unknown
- 2015-10-29 EP EP15855147.3A patent/EP3212226B1/en active Active
- 2015-10-29 SG SG11201702580PA patent/SG11201702580PA/en unknown
- 2015-10-29 ES ES15855147T patent/ES2799503T3/es active Active
- 2015-10-29 MY MYPI2017701500A patent/MY186702A/en unknown
- 2015-10-29 EP EP20156349.1A patent/EP3701969A1/en active Pending
- 2015-10-29 KR KR1020177006910A patent/KR102672706B1/ko active Active
-
2017
- 2017-03-09 IL IL251066A patent/IL251066B/en active IP Right Grant
- 2017-04-07 CL CL2017000864A patent/CL2017000864A1/es unknown
- 2017-04-07 SV SV2017005420A patent/SV2017005420A/es unknown
- 2017-04-07 GT GT201700072A patent/GT201700072A/es unknown
- 2017-04-07 EC ECIEPI201721754A patent/ECSP17021754A/es unknown
- 2017-04-07 NI NI201700042A patent/NI201700042A/es unknown
- 2017-04-10 CO CONC2017/0003487A patent/CO2017003487A2/es unknown
- 2017-04-10 PH PH12017500680A patent/PH12017500680A1/en unknown
- 2017-04-11 DO DO2017000097A patent/DOP2017000097A/es unknown
-
2018
- 2018-01-31 US US15/885,438 patent/US10562965B2/en active Active
-
2020
- 2020-01-15 US US16/743,712 patent/US11530260B2/en active Active
-
2022
- 2022-11-07 US US17/982,390 patent/US12173060B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171058A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| MX2016015868A (es) | Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina. | |
| BR112016020368A2 (pt) | proteínas fc multiméricas | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| CL2016001405A1 (es) | A peptide mixture | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| BR112019023071A2 (pt) | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| DOP2015000020A (es) | Proteínas de fusión para el tratamiento de un síndrome metabólico | |
| PE20161440A1 (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| MX2023014921A (es) | Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. | |
| BR112017012928A2 (pt) | uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste | |
| PE20190117A1 (es) | Compuestos de mic-1 y usos de estos | |
| BR112019000732A2 (pt) | métodos e composições para o tratamento de câncer | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
| PH12019501108A1 (en) | Anti-gitr anti-binding protein and methods of use thereof | |
| CU20210008A7 (es) | Aspirasas solubilizadas | |
| BR112013025975A2 (pt) | proteína de fusão anticancerígena | |
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| CR20160369A (es) | Composiciones para uso en el tratamiento de afecciones alérgicas |